Elective Percutaneous Coronary Intervention in Ambulatory Surgery Centers

被引:6
|
作者
Li, Kevin [1 ]
Kalwani, Neil M. [2 ]
Heidenreich, Paul A. [2 ]
Fearon, William F. [2 ]
机构
[1] Stanford Univ, Dept Med, Stanford, CA 94305 USA
[2] Stanford Univ, Dept Med, Stanford Cardiovasc Inst, Div Cardiovasc Med, 300 Pasteur Dr,H2103, Stanford, CA 94305 USA
基金
美国国家卫生研究院;
关键词
ischemic heart disease; outcomes; PCI; percutaneous coronary intervention; health services research; SAME-DAY DISCHARGE; TEMPORAL TRENDS; ANGIOGRAPHY; MORTALITY; OUTCOMES; ACCESS; IMPACT; RISK; SITE;
D O I
10.1016/j.jcin.2020.10.015
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
OBJECTIVES The aim of this study was to explore characteristics and outcomes of patients undergoing elective percutaneous coronary intervention (PCI) in ambulatory surgery centers (ASCs). BACKGROUND Little is known about patients who underwent ASC PCI before Medicare reimbursement was instituted in 2020. METHODS Using commercial insurance claims from MarketScan, adults who underwent hospital outpatient department (HOPD) or ASC PCI for stable ischemic heart disease from 2007 to 2016 were studied. Propensity score analysis was used to measure the association between treatment setting and the primary composite outcome of 30-day myocardial infarction, bleeding complications, and hospital admission. RESULTS The unmatched sample consisted of 95,492 HOPD and 849 ASC PCIs. Patients who underwent ASC PCI were more likely to be younger than 65 years, to live in the southern United States, and to have managed or consumer-driven health insurance. ASC PCI was also associated with decreased fractional flow reserve utilization (odds ratio [OR]: 0.31; 95% confidence interval [CI]: 0.20 to 0.48; p < 0.001). In unmatched, multivariate analysis, ASC PCI was associated with increased odds of the primary outcome (OR: 1.25; 95% CI: 1.01 to 1.56; p = 0.039) and bleeding complications (OR: 1.80; 95% CI: 1.11 to 2.90; p = 0.016). In propensity-matched analysis, ASC PCI was not associated with the primary outcome (OR: 1.23; 95% CI: 0.94 to 1.60; p = 0.124) but was significantly associated with increased bleeding complications (OR: 2.49; 95% CI: 1.25 to 4.95; p = 0.009). CONCLUSIONS Commercially insured patients undergoing ASC PCI were less likely to undergo fractional flow reserve testing and had higher odds of bleeding complications than HOPD-treated patients. Further study is warranted as Medicare ASC PCI volume increases. (J Am Coll Cardiol Intv 2021;14:292-300) Published by Elsevier on behalf of the American College of Cardiology Foundation
引用
收藏
页码:292 / 300
页数:9
相关论文
共 50 条
  • [31] Aspirin IV Loading during Elective Percutaneous Coronary Intervention
    Naguib, David
    Helten, Carolin
    Zako, Saif
    Mourikis, Philipp
    M'Pembele, Rene
    Trojovsky, Kajetan
    Ahlbrecht, Samantha
    Zikeli, Dorothee
    Zeus, Tobias
    Kelm, Malte
    Dannenberg, Lisa
    Polzin, Amin
    PHARMACOLOGY, 2021, 106 (11-12) : 682 - 686
  • [32] Low-Dose Heparin for Elective Percutaneous Coronary Intervention
    Lee, Michael S.
    Oyama, Jared
    Iqbal, Zahid
    Tarantini, Giuseppe
    JOURNAL OF INTERVENTIONAL CARDIOLOGY, 2014, 27 (01) : 58 - 62
  • [33] Early Clinical and Echocardiographic Effects of Elective Percutaneous Coronary Intervention
    Amin, Mohamed
    El Hosieny, Rania
    Ragab, Dalia
    Wadie, Ashraf
    LIFE SCIENCE JOURNAL-ACTA ZHENGZHOU UNIVERSITY OVERSEAS EDITION, 2011, 8 (04): : 1068 - 1077
  • [34] Antiplatelet Therapy in Patients Undergoing Elective Percutaneous Coronary Intervention
    Alkhalil, Mohammad
    Dzavik, Vladimir
    Bhatt, Deepak L.
    Mehran, Roxana
    Mehta, Shamir R.
    CURRENT CARDIOLOGY REPORTS, 2022, 24 (03) : 277 - 293
  • [35] ISCHEMIA MODIFIED ALBUMIN AFTER ELECTIVE PERCUTANEOUS CORONARY INTERVENTION
    Sygitowicz, G.
    Pregowski, J.
    Bialek, S.
    Sitkiewicz, D.
    CLINICAL CHEMISTRY AND LABORATORY MEDICINE, 2011, 49 : S344 - S344
  • [36] Antiplatelet Therapy in Patients Undergoing Elective Percutaneous Coronary Intervention
    Mohammad Alkhalil
    Vladimír Džavík
    Deepak L. Bhatt
    Roxana Mehran
    Shamir R. Mehta
    Current Cardiology Reports, 2022, 24 : 277 - 293
  • [37] GP IIb/IIIa blockade in elective percutaneous coronary intervention
    Dery, JP
    Harrington, RA
    Tcheng, JE
    CURRENT PHARMACEUTICAL DESIGN, 2004, 10 (04) : 387 - 398
  • [38] Low dose intravenous enoxaparin in elective percutaneous coronary intervention
    Choussat, R
    Montalescot, G
    Collet, JP
    Gallois, V
    Sotirov, Y
    Drobinski, G
    Thomas, D
    CIRCULATION, 2001, 104 (17) : 706 - 706
  • [39] AFFECTION FOR ELECTIVE PERCUTANEOUS CORONARY INTERVENTION WITH HIGH DOSE CLOPIDOGREL
    Wang ShiHong
    Xu Aibin
    Wang Xi
    Wang Shihong
    HEART, 2013, 99 : E163 - E164
  • [40] Elective percutaneous coronary intervention in outpatients is safe: a randomized trial
    Heyde, GS
    Koch, KT
    Tijssen, JGP
    Klees, MI
    Dijkgraaf, MGW
    Dijksman, LM
    de Winter, RJ
    Piek, JJ
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2005, 45 (03) : 346A - 347A